The following is a summary of “Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study,” published in the March 2025 issue of Rheumatology by Westermann et al. Researchers conducted a retrospective study to compare cancer risk in patients with RA treated with tocilizumab/sarilumab, abatacept, or rituximab against […]
The post Cancer Risk in RA Treated With Tocilizumab, Sarilumab, Abatacept, or Rituximab first appeared on Physician’s Weekly.
